Get started
Author

Ifeyinwa Osunkwo

Observed names: I Osunkwo, I. Osunkwo, Ifeyinwa (IFY) Osunkwo, Ifeyinwa (Ify) Osunkwo, Ifeyinwa (ify) Osunkwo
Observed institutions: Carolinas Healthcare System, Novo Nordisk (Denmark), University of Michigan, Columbia University Irving Medical Center, Carolinas Medical Center, University of Florida, Levine Cancer Institute, Novo Nordisk (Switzerland), Wake Forest University, Columbia University
ORCID: 0009-0007-8041-5853
Observed ORCIDs: 0009-0007-8041-5853, 0000-0002-0996-2148
OpenAlex ID: A5102859152
Impact of sickle cell disease on patientsʼ daily lives, symptoms reported, and disease management strategies: Results from the international Sickle Cell World Assessment Survey ( SWAY )
2020 · Ifeyinwa Osunkwo, Biree Andemariam, et al. · American Journal of Hematology · 195
PDF
American Society of Hematology 2019 guidelines for sickle cell disease: cardiopulmonary and kidney disease
2019 · Robert I. Liem, Sophie Lanzkron, et al. · Blood Advances · 183
PDF
Building access to care in adult sickle cell disease: defining models of care, essential components, and economic aspects
2020 · Julie Kanter, Wally R. Smith, et al. · Blood Advances · 125
PDF
Safety and efficacy of allogeneic PBSC collection in normal pediatric donors: The Pediatric Blood and Marrow Transplant Consortium Experience (PBMTC) 1996–2003
2004 · M A Pulsipher, J E Levine, et al. · Bone Marrow Transplantation · 110
A pilot study of tacrolimus and mycophenolate mofetil graft-versus-host disease prophylaxis in childhood and adolescent allogeneic stem cell transplant recipients
2004 · Ifeyinwa Osunkwo, Olga Bessmertny, et al. · Transplantation and Cellular Therapy · 97
PDF
Current and novel therapies for the prevention of vaso-occlusive crisis in sickle cell disease
2020 · Ifeyinwa Osunkwo, Deepa Manwani, et al. · Therapeutic Advances in Hematology · 52
PDF
Immune parameter analysis of children with sickle cell disease on hydroxycarbamide or chronic transfusion therapy
2015 · Robert S. Nickel, Ifeyinwa Osunkwo, et al. · British Journal of Haematology · 45
PDF
Multicenter, phase 1 study of etavopivat (FT-4202) treatment for up to 12 weeks in patients with sickle cell disease
2024 · Santosh L. Saraf, Robert Hagar, et al. · Blood Advances · 32
PDF
Microarchitectural and mechanical characterization of the sickle bone
2015 · Mykel Green, Idowu Akinsami, et al. · Journal of the mechanical behavior of biomedical materials/Journal of mechanical behavior of biomedical materials · 27
Burden of disease, treatment utilization, and the impact on education and employment in patients with sickle cell disease: A comparative analysis of high‐ and low‐ to middle‐income countries for the international Sickle Cell World Assessment Survey
2022 · Ifeyinwa Osunkwo, John James, et al. · American Journal of Hematology · 19
PDF
Emotion-Focused Avoidance Coping Mediates the Association Between Pain and Health-Related Quality of Life in Children With Sickle Cell Disease
2019 · Crystal S. Lim, Cynthia Karlson, et al. · Journal of Pediatric Hematology/Oncology · 15
Opening Pandora’s Box
2021 · Mathew J. Reeves, Michele C. Fritz, et al. · Medical Care · 12
Shared Decision-Making in Hematopoietic Stem Cell Transplantation for Sickle Cell Disease
2018 · Keith M. Sullivan, Mitchell Horwitz, et al. · Transplantation and Cellular Therapy · 12
Gender differences in question-asking at the 2019 American Society of Hematology Annual Meeting
2020 · Saira Moazzam, Lynn Onstad, et al. · Blood Advances · 10
PDF
A comparison of the effect of patient‐specific versus weight‐based protocols to treat vaso‐occlusive episodes in the emergency department
2023 · Paula Tanabe, Stephanie Ibemere, et al. · Academic Emergency Medicine · 9
PDF
Use of Buprenorphine/Naloxone in Ameliorating Acute Care Utilization and Chronic Opioid Use in Adults with Sickle Cell Disease
2019 · Ifeyinwa (ify) Osunkwo, Padmaja Veeramreddy, et al. · Blood · 7
Results of a healthcare transition learning collaborative for emerging adults with sickle cell disease: the ST3P-UP study transition quality improvement collaborative
2024 · Ifeyinwa Osunkwo, Jennifer S Cornette, et al. · BMJ Quality & Safety · 6
Successful quality improvement project to increase hydroxyurea prescriptions for children with sickle cell anaemia
2023 · Ofelia A Alvarez, Hector Rodriguez-Cortes, et al. · BMJ Quality & Safety · 5
Sickle Cell Trevor Thompson Transition Project (ST3P-UP) protocol for managing care transitions: Methods and rationale
2023 · Ifeyinwa Osunkwo, Raymona Lawrence, et al. · Contemporary Clinical Trials · 5
Management Strategies and Satisfaction Levels in Patients with Sickle Cell Disease: Interim Results from the International Sickle Cell World Assessment Survey (SWAY)
2019 · John James, Biree Andemariam, et al. · Blood · 5
Implicit bias in pain management: The intersection of stigma, race, and chronic disease in sickle cell disease
2026 · Christopher L. Edwards, Ashley S. Membreno Lopez, et al. · Journal of the National Medical Association · 4
Real-World Experience of Patients with Sickle Cell Disease Treated with Voxelotor: A Multicenter, Retrospective Study
2021 · Biree Andemariam, Maureen Achebe, et al. · Blood · 4
Experiences of Sickle Cell Disease (SCD) Reported By Healthcare Professionals (HCPs) across Different Regions: International Sickle Cell World Assessment Survey (SWAY)
2021 · Ifeyinwa Osunkwo, Biree Andemariam, et al. · Blood · 3
Global Treatment Satisfaction Levels and Treatment Patterns from the International Sickle Cell World Assessment Survey (SWAY): Hydroxyurea (HU) Versus No HU
2020 · Fuad A El Rassi, John James, et al. · Blood · 3
Impact of Sickle Cell Disease Symptoms on Patients' Daily Lives: Interim Results from the International Sickle Cell World Assessment Survey (SWAY)
2019 · Ifeyinwa (ify) Osunkwo, Biree Andemariam, et al. · Blood · 3
Works count: 63
Citation count: 1,004
H-index: 12
I10-index: 14
Year
Topic
Type